Immunogenicity of engineered antibodies

Methods. 2005 May;36(1):3-10. doi: 10.1016/j.ymeth.2005.01.001.


Administration of a therapeutic antibody can lead to an anti-antibody response (AAR). Much effort has been applied to engineering antibodies with as little as possible non-human structure to minimize such responses. Here, we review reported AAR to murine, mouse-human chimeric, and humanized antibodies. Replacement of mouse immunoglobulin constant regions with human ones effects the largest immunogenicity reduction. Humanization of variable domains effects a further decrease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / genetics*
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibody Specificity
  • Humans
  • Immunoglobulin Constant Regions / genetics
  • Immunoglobulin Constant Regions / immunology
  • Mice
  • Protein Engineering
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology


  • Antibodies, Monoclonal
  • Immunoglobulin Constant Regions
  • Recombinant Fusion Proteins